We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PII and NexMed Enter Collaboration Agreement for NexMed’s NexACT® Drug Delivery Platform

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "PII and NexMed Enter Collaboration Agreement for NexMed’s NexACT® Drug Delivery Platform"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
PII, (Pharmaceutics International, Inc.) and NexMed, Inc. announced that they have signed a Memorandum of Understanding (MOU) for a strategic product development collaboration utilizing NexMed’s NexACT drug delivery platform.

Pursuant to the MOU, PII will promote the NexACT technology to its clients and may independently identify new product development opportunities for this collaboration with NexMed.

PII will be responsible for the research and development of the new pharmaceutical products with technical guidance and oversight from NexMed, and will also assume responsibility for clinical trial material manufacturing and commercial manufacturing of the new products.

Hem Pandya, NexMed’s COO said, “We are very pleased to enter into this collaboration with PII. The strategic goal is to broaden the promotion of our technology and permit us access to PII’s research and development and commercial manufacturing infrastructure. We will also be able to continue with our current product development efforts at significantly reduced monthly overhead expenses.”

Steve King, PII’s Senior Vice President said, “The collaboration between the companies will offer PII’s customers opportunities for product development without having to move their compounds elsewhere. The NexACT technology fits well with PII’s Drug Delivery Solutions initiative.”